Abstract
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? The transmission of emerging and re-emerging arboviruses represent a critical challenge to blood transfusion safety worldwide. WHAT IS ADDED BY THIS REPORT? This study established a comprehensive quality assurance system for Dengue virus (DENV), Zika virus (ZIKV), and Chikungunya virus (CHIKV) nucleic acid testing (NAT) blood screening. The system included external quality assessment (EQA) implementation across all participating central blood stations and performance evaluation of six domestic blood screening reagents. Surveillance conducted in Yunnan Province and Guangxi Zhuang Autonomous Region revealed no positive cases among 45,383 blood samples screened in 2022. In 2023, screening of 44,972 blood donors identified 9 NAT-reactive samples at the Xishuangbanna central blood station, with 6 confirmed as DENV-1 positive. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE? Blood stations in border regions must implement comprehensive surveillance systems with enhanced detection sensitivity and robust early warning mechanisms to effectively address emerging disease threats and ensure transfusion safety.